Litcius/Paper detail

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Catherine A. Shu, Justin F. Gainor, Mark M. Awad, Codruța Chiuzan, Claud Grigg, Aliyah Pabani, Robert F. Garofano, Mark Stoopler, Simon K. Cheng, Abby White, Michael Lanuti, F. D’Ovidio, Matthew Bacchetta, Joshua Sonett, Anjali Saqi, Naiyer A. Rizvi

2020The Lancet Oncology640 citationsDOI

Topics & Concepts

AtezolizumabMedicineCarboplatinClinical endpointLung cancerPerioperativeInternal medicineOncologyChemotherapyNeoadjuvant therapyPaclitaxelCancerClinical trialSurgeryCisplatinBreast cancerImmunotherapyNivolumabCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Research Studies
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial | Litcius